Vaccinex, Inc. to Present at the Ladenburg Thalmann 2018 Healthcare Conference
ROCHESTER, N.Y., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announced its CEO, Maurice Zauderer, Ph.D., will present and meet with investors at the Ladenburg Thalmann 4th Annual Healthcare Conference on October 2, 2018. The company will present at 8:30 AM ET as part of Track 6 in the Madeleine Room at the Sofitel in New York City. Investors interested in one-on-one meetings should contact the conference organizers or Michael Rice from LifeSci Advisors at mrice@lifesciadvisors.com. About Vaccinex, Inc. Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer
[Read more]
| Impact snapshot | Event time: | VCNX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
VCNX alerts
VCNX alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCNX alerts
High impacting Vaccinex, Inc. news events
Weekly update
A roundup of the hottest topics
VCNX
News
- Vaccinex's pepinemab combo study shows encouraging activity in lung cancer [Seeking Alpha]Seeking Alpha
- Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer ResearchGlobeNewswire
- Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswire
- Vaccinex to Present at the Oppenheimer 31st Annual Healthcare ConferenceGlobeNewswire
- Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface OncologyGlobeNewswire
- More
VCNX
SEC Filings
- 5/12/21 - Form 4
- 5/12/21 - Form 4
- 5/12/21 - Form 4
- VCNX's page on the SEC website
- More